Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPN536
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HPN536 is a trispecific T-cell activating construct (TriTAC) designed for cancer immunotherapy. It is a recombinant protein-based drug that simultaneously binds to mesothelin (MSLN) on tumor cells, CD3ε on T cells, and serum albumin. By engaging both the tumor antigen mesothelin and the CD3 receptor on T cells, HPN536 redirects and activates T cells to kill mesothelin-expressing cancer cells. The albumin-binding domain extends its plasma half-life. Developed initially by Harpoon Therapeutics, it was later acquired by Merck & Co. The drug has been investigated primarily for advanced cancers associated with mesothelin expression, including ovarian cancer, pancreatic cancer, lung cancer, and mesothelioma[1][2][3][4][5][6].
- Other names
- 2 Prime Step IV-Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)-ovarian cancer-fallopian tube cancer-primary peritoneal cancer-pancreatic adenocarcinoma-malignant mesothelioma
02
Targets
CD3 (T-cell surface glycoprotein CD3)Mesothelin
Beyond the preview
Go deeper on HPN536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPN536.